X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (134) 134
index medicus (111) 111
hematology (90) 90
middle aged (90) 90
adult (85) 85
female (73) 73
male (71) 71
leukemia, myeloid, acute - genetics (65) 65
prognosis (59) 59
oncology (57) 57
adolescent (53) 53
acute myeloid leukemia (43) 43
aged (43) 43
leukemia, myeloid, acute - mortality (38) 38
mutation (38) 38
treatment outcome (36) 36
young adult (36) 36
cancer (33) 33
abridged index medicus (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
leukemia (28) 28
leukemia, myeloid, acute - drug therapy (27) 27
leukemia, myeloid, acute - therapy (26) 26
aml (25) 25
acute myelogenous leukemia (24) 24
aged, 80 and over (23) 23
acute myeloid-leukemia (22) 22
leukemia, myeloid, acute - diagnosis (22) 22
mutations (22) 22
adult patients (21) 21
chemotherapy (21) 21
prospective studies (20) 20
survival rate (20) 20
chromosome aberrations (19) 19
survival analysis (19) 19
karyotyping (18) 18
remission induction (18) 18
acute disease (17) 17
disease-free survival (17) 17
high-dose cytarabine (17) 17
minimal residual disease (17) 17
nuclear proteins - genetics (17) 17
stem-cell transplantation (17) 17
trial (17) 17
group-b (16) 16
leukemia, myeloid, acute - pathology (16) 16
fms-like tyrosine kinase 3 - genetics (15) 15
gene expression profiling (15) 15
research (15) 15
adults (14) 14
kaplan-meier estimate (14) 14
leukemia, myeloid - genetics (14) 14
myelodysplastic syndromes (14) 14
postremission therapy (14) 14
risk factors (14) 14
survival (14) 14
cohort studies (13) 13
gene expression (13) 13
internal tandem duplication (13) 13
transplantation, homologous (13) 13
follow-up studies (12) 12
normal cytogenetics (12) 12
acute promyelocytic leukemia (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
biomarkers, tumor - genetics (11) 11
germany (11) 11
leukemia, myeloid, acute - metabolism (11) 11
prognostic-significance (11) 11
transplantation (11) 11
tretinoin - administration & dosage (11) 11
younger adults (11) 11
animals (10) 10
classification (10) 10
hematopoietic stem cell transplantation (10) 10
hemic and lymphatic diseases (10) 10
recurrence (10) 10
risk assessment (10) 10
therapy (10) 10
trans-retinoic acid (10) 10
translocation, genetic (10) 10
article (9) 9
clinical trials (9) 9
cytarabine - administration & dosage (9) 9
gene (9) 9
genetics & heredity (9) 9
health aspects (9) 9
normal karyotype (9) 9
older patients (9) 9
patients (9) 9
risk (9) 9
acute myeloid leukaemia (8) 8
age factors (8) 8
analysis (8) 8
colony-stimulating factor (8) 8
cytarabine (8) 8
cytogenetics (8) 8
diagnosis (8) 8
expression (8) 8
favorable prognosis (8) 8
gemtuzumab ozogamicin (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 156 - 157
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages
Journal Article
Seminars in Hematology, ISSN 0037-1963, 04/2019, Volume 56, Issue 2, pp. 96 - 101
Intensive induction chemotherapy followed by postremission treatment with either high-dose cytarabine-based regimens, autologous or allogeneic hematopoietic... 
YOUNGER PATIENTS | ADULT PATIENTS | GEMTUZUMAB OZOGAMICIN | POSTREMISSION THERAPY | IDH2 MUTATIONS | OLDER PATIENTS | HIGH-DOSE CYTARABINE | PROGNOSTIC RELEVANCE | ACUTE MYELOID-LEUKEMIA | HEMATOLOGY | MINIMAL RESIDUAL DISEASE
Journal Article
Recent Results in Cancer Research, ISSN 0080-0015, 2018, Volume 212, pp. 199 - 214
Midostaurin (PKC412, Rydapt ) is an oral multiple tyrosine kinase inhibitor. Main targets are the kinase domain receptor, vascular endothelial-, platelet... 
AML with activating FLT3 mutations | Multikinase inhibitor | Systemic mastocytosis
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 4064 - 4064
Abstract Background: Essential thrombocythemia (ET) is a chronic myeloid stem cell disorder characterized by an uncontrolled production of platelets. Common... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 23, pp. 2209 - 2221
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 3744 - 3744
Abstract Purpose: We evaluated whether event-free survival (EFS) can be used as a surrogate for overall survival (OS) in patients treated for acute myeloid... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 111 - 121
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 3756 - 3756
Abstract The hypomethylating agent decitabine (DAC) represents a therapeutic option for acute myeloid leukemia (AML) patients who are not eligible for an... 
Journal Article
Journal Article